Engineering of Layer-By-Layer Acetate Coated Paclitaxel Loaded Poly(lactide-Co-Glycolide) Acid Nanoparticles for Prostate Cancer Therapy- In Vitro.

It hypothesized that layer-by-layer acetate-coated Paclitaxel-loaded PLGA nanoparticles (F2) can be engineered to potentiate the effectiveness of Paclitaxel (PTX) on LNCaP, a human prostate cancer cell line. The core of the layer-by-layer NPs is formed by nanoprecipitation, and the shell of the NPs is engineered using the sodium acetate's unique coating mechanism and surface-active properties. The resulting nanoformulation physicochemical properties are characterized by Fourier Transform Infra-Red (FTIR), Differential Scanning Calorimetry (DSC) Transmission Electron Microscopy (TEM), NanoSight NS300, spectrophotometry, Korsmeyer-Peppas model, respectively. The NP's cytotoxicity on LNCaP is assessed by MTS assay. The DSC and the FTIR confirm SA's coating of the NPs. The particle's mean diameters (PMD) are 89.4±2.3- to 114.4±7.6 nm. The TEM showed a unique multilayer and spherical nanoparticle. The encapsulation efficiency of commonly PTX-loaded PLGA NPs (F1) and F2 are 84.37±2.71% and 86.74±2.22, respectively. The drug transport mechanism of F1 and F2 is anomalous transport and case II, respectively. F2 follows a zero-order release mechanism. The cell viability is 45.08±2.18% and 60.17±4.72% when LNCaP is treated with 10 µg/mL of F2 and F1, respectively, after 48 hours of exposure. F2 and F1 cell growth inhibition are dose-dependent. This unique process of engineering the layer-by-layer NPs will provide new horizons for developing future innovative nanoparticles for targeted prostate cancer therapy.

• Publication year

  2024

• Venue

  Journal of Pharmacy and Science

• Publication date

  2024-09-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.xphs.2024.09.014PMID 39313154PMCID PMC12084874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A simple and cost-effective technique to monitor the sublimation flow during primary drying of freeze-drying using shelf inlet/outlet temperature difference or chamber to condenser pressure drop.

  2024cited by this paper
• Integrated multi‐omics analysis reveals unique signatures of paclitaxel‐loaded poly(lactide‐co‐glycolide) nanoparticles treatment of head and neck cancer cells

  2023cited by this paper
• Physico-chemistry and Cytotoxicity of Tenofovir-Loaded Acid Phosphatase-Responsive Chitosan Nanoparticles

  2023cited by this paper
• Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer

  2021cited by this paper
• Preparation and characterization of Docetaxel-PLGA nanoparticles coated with folic acid-chitosan conjugate for cancer treatment.

  2021cited by this paper
• The Hydrolysis of Phosphinates and Phosphonates: A Review

  2021cited by this paper
• Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort

  2021cited by this paper
• Prostate-specific membrane antigen (PSMA)–ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer

  2020cited by this paper
• Prevention of paclitaxel-induced neuropathy by formulation approach.

  2019cited by this paper
• PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer

  2019cited by this paper
• Engineering fast dissolving sodium acetate mediated crystalline solid dispersion of docetaxel

  2018cited by this paper
• Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

  2018cited by this paper
• Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer

  2018cited by this paper
• Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer.

  2017cited by this paper
• Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing in vitro and prolonged circulation in vivo.

  2016cited by this paper
• Sodium Acetate Coated Tenofovir-Loaded Chitosan Nanoparticles for Improved Physico-Chemical Properties

  2016cited by this paper
• Cytotoxic and antiangiogenic paclitaxel solubilized and permeation-enhanced by natural product nanoparticles

  2015cited by this paper
• HaCaT Keratinocytes Response on Antimicrobial Atelocollagen Substrates: Extent of Cytotoxicity, Cell Viability and Proliferation

  2014cited by this paper
• Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

  2014cited by this paper
• Nanoparticle therapeutics for prostate cancer treatment.

  2012cited by this paper
• Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions

  2011cited by this paper
• Alcohol intoxication with the new formulation of docetaxel.

  2011cited by this paper
• Fabrication via a nonaqueous nanoprecipitation method, characterization and in vitro biological behavior of N(6)-cyclopentyladenosine-loaded nanoparticles.

  2009cited by this paper
• Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen.

  2008cited by this paper
• Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake.

  2002cited by this paper
• Modeling and comparison of dissolution profiles.

  2001cited by this paper
• Mechanisms of solute and drug transport in relaxing, swellable, hydrophilic glassy polymers

  1999cited by this paper
• Paclitaxel in the treatment of hormone-refractory prostate cancer.

  1999cited by this paper

• No citing papers are available for this paper.